NTF4 plays a dual role in breast cancer in mammary tumorigenesis and metastatic progression.
Ran Sun,Jin He,Qin Xiang,Yixiao Feng,Yijia Gong,Yijiao Ning,Chaoqun Deng,Kexin Sun,Mingjun Zhang,Zhaobo Cheng,Xin Le,Qi Xiong,Fengsheng Dai,Yongzhong Wu,Tingxiu Xiang
DOI: https://doi.org/10.7150/ijbs.79435
2023-01-01
International Journal of Biological Sciences
Abstract:Breast cancer metastasis can happen even when the primary tumor is relatively small. But the mechanism for such early metastasis is poorly understood. Herein, we report that neurotrophin 4 (NTF4) plays a dual role in breast cancer proliferation and metastasis. Clinical data showed high levels of NTF4, especially in the early stage, to be associated with poor clinical outcomes, supporting the notion that metastasis, rather than primary cancer, was the major determinant of breast cancer mortality for patients. NTF4 promoted epithelial-mesenchymal transition (EMT), cell motility, and invasiveness of breast cancer cells and . Interestingly, NTF4 inhibited cell proliferation while promoting cellular apoptosis and inhibited xenograft tumorigenicity . Mechanistically, NTF4 elicited its pro-metastatic effects by activating PRKDC/AKT and ANXA1/NF-κB pathways to stabilize SNAIL protein, therefore decreasing the level of E-cadherin. Conversely, NTF4 increased ANXA1 phosphorylation and sumoylation and the interaction with importin β, leading to nuclear import and retention of ANXA1, which in turn activates the caspase-3 apoptosis cascade. Our findings identified an unexpected dual role for NTF4 in breast cancer which contributes to early metastasis of the disease. Therefore, NTF4 may serve as a prognostic marker and a potential therapeutic target for breast cancer.